Measles, mumps and rubella combined vaccine, live attenuated (Beijing Minhai Biotech)

麻腮风联合减毒活疫苗（北京民海生物科技）

Report date: 2026/03/30 20:02:02

Base Information

Drug NameMeasles, mumps and rubella combined vaccine, live attenuated (Beijing Minhai Biotech)
Drug Alias NameMeasles/mumps/rubella vaccine (live-attenuated)
ClassificationVaccines > Application > Prophylactic vaccineVaccines > Development/production technology > Live attenuated vaccineVaccines > Vaccine type > Combination vaccine +[4] 
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsParotitisRubellaRubivirus Infections +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesBeijing Minhai Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBeijing Minhai Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsParotitisRubellaRubivirus Infections +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A